1. [CASE 1 — QUESTION 1]
A 56-year-old man with type 2 diabetes is inadequately controlled on metformin monotherapy. He is markedly insulin-resistant, has an atherogenic lipid profile (elevated triglycerides, low HDL-C [high-density lipoprotein cholesterol]), has no heart failure, and has normal bone mineral density. His clinician is considering adding pioglitazone. Which statement best supports selecting pioglitazone in this specific patient?
A) Pioglitazone is preferred because it stimulates glucose-dependent insulin secretion, reducing hypoglycemia risk
B) Pioglitazone is reasonable because its dual PPAR-gamma/PPAR-alpha activity improves the atherogenic lipid profile, and this patient lacks the heart failure and bone-fragility features that would otherwise contraindicate a thiazolidinedione
C) Pioglitazone is preferred because it produces rapid glycemic lowering within 48 hours
D) Pioglitazone is the best choice because it causes substantial weight loss that will improve insulin resistance
E) Pioglitazone is selected because it acts in the intestinal lumen to blunt postprandial glucose without systemic effects
ANSWER: B
Rationale:
Pioglitazone activates PPAR-gamma (peroxisome proliferator-activated receptor gamma) and, to a lesser degree, PPAR-alpha (peroxisome proliferator-activated receptor alpha), which raises HDL-C (high-density lipoprotein cholesterol) and lowers triglycerides, suiting this atherogenic profile; because the patient has no heart failure and normal bone density, the two liabilities that would otherwise contraindicate or strongly caution against a thiazolidinedione are absent.
Option A: Option A is incorrect because pioglitazone is an insulin sensitizer and does not stimulate insulin secretion.
Option C: Option C is incorrect because the maximal glycemic effect of thiazolidinediones is delayed 6 to 12 weeks, not 48 hours.
Option D: Option D is incorrect because thiazolidinediones cause weight gain, not weight loss.
Option E: Option E is incorrect because intestinal-lumen action describes alpha-glucosidase inhibitors, not pioglitazone, which acts on a nuclear receptor.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. Pioglitazone is started. At a follow-up visit three weeks later, he is tolerating the drug well with no edema, but his home glucose readings have improved only modestly. He asks whether the medication is working. What is the most appropriate counseling?
A) Stop pioglitazone, because the lack of full response at three weeks confirms treatment failure
B) Add prandial insulin immediately, since pioglitazone has clearly failed
C) Switch to rosiglitazone, which produces an immediate glycemic effect
D) Reassure him and continue pioglitazone, because the maximal glycemic effect of thiazolidinediones is delayed 6 to 12 weeks owing to their gene-expression-dependent mechanism
E) Double the dose now to force a faster response
ANSWER: D
Rationale:
Thiazolidinediones act through PPAR-gamma (peroxisome proliferator-activated receptor gamma)-driven changes in gene expression and protein synthesis, so their maximal glycemic effect is delayed 6 to 12 weeks; a modest response at three weeks in a well-tolerating patient is expected, and the correct action is reassurance and continuation.
Option A: Option A is incorrect because three weeks is too early to declare failure given the known delayed onset.
Option B: Option B is incorrect because adding insulin is premature before the thiazolidinedione has reached full effect.
Option C: Option C is incorrect because rosiglitazone shares the same delayed, gene-expression-dependent time course and does not act immediately.
Option E: Option E is incorrect because dose escalation does not accelerate the inherently delayed onset and raises adverse-effect risk.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. After three months on pioglitazone his glucose control is good, but he now reports a 4 kg weight gain, new bilateral ankle edema, and exertional dyspnea. Examination and workup are consistent with new fluid overload. What is the most appropriate next step?
A) Discontinue pioglitazone, because thiazolidinedione-induced sodium and fluid retention is producing volume overload
B) Continue pioglitazone and attribute the findings entirely to dietary indiscretion
C) Increase the pioglitazone dose, since the weight gain reflects improved anabolism
D) Continue pioglitazone and simply restrict fluids without changing the drug
E) Switch to rosiglitazone, which does not cause fluid retention
ANSWER: A
Rationale:
The new weight gain, edema, and dyspnea reflect thiazolidinedione fluid retention, driven by PPAR-gamma (peroxisome proliferator-activated receptor gamma)-mediated upregulation of the epithelial sodium channel (ENaC) in the collecting duct, which expands extracellular volume; the appropriate response to symptomatic volume overload is to discontinue the drug.
Option B: Option B is incorrect because the temporal link to pioglitazone and the clear fluid-overload picture point to a drug effect, not diet alone.
Option C: Option C is incorrect because the weight gain is fluid retention, so increasing the dose would worsen it.
Option D: Option D is incorrect because fluid restriction without stopping the causative drug does not address the underlying mechanism.
Option E: Option E is incorrect because fluid retention is a class effect of thiazolidinediones, so rosiglitazone shares it and also carries an unfavorable cardiovascular profile.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Pioglitazone is stopped and his fluid overload resolves with diuresis. He remains above his glycemic goal on metformin alone. He has stage 2 chronic kidney disease (CKD), a prior wrist fracture, and the heart failure features just observed. Which add-on agent best fits the constraints now evident?
A) A second thiazolidinedione, since the prior fluid problem was idiosyncratic
B) A sulfonylurea, because non-glucose-dependent secretion is ideal given his comorbidities
C) A DPP-4 inhibitor such as sitagliptin or linagliptin, because it is weight- and fluid-neutral, carries low hypoglycemia risk, and avoids the bone and fluid liabilities that now constrain him
D) Acarbose, which is the preferred agent in established heart failure
E) Rosiglitazone, because its skeletal profile is favorable after a fracture
ANSWER: C
Rationale:
After thiazolidinedione-induced heart failure, with a prior fragility fracture and CKD, the patient needs an agent that is weight- and fluid-neutral, low-risk for hypoglycemia, and free of bone liability; a DPP-4 (dipeptidyl peptidase-4) inhibitor such as sitagliptin or linagliptin fits all of these constraints, with linagliptin needing no renal adjustment.
Option A: Option A is incorrect because thiazolidinedione fluid retention is a class effect, not idiosyncratic, so re-exposure would risk recurrence.
Option B: Option B is incorrect because a sulfonylurea's non-glucose-dependent secretion raises hypoglycemia risk and offers no advantage here.
Option D: Option D is incorrect because acarbose is not preferred in heart failure and addresses only postprandial glucose.
Option E: Option E is incorrect because rosiglitazone shares the thiazolidinedione fracture and fluid liabilities and has an unfavorable cardiovascular profile.
5. [CASE 2 — QUESTION 1]
A 79-year-old woman with type 2 diabetes and stage 4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] 23 mL/min/1.73m2) is above her HbA1c goal on metformin. She has a history of falls and no heart failure. Her clinician wants a DPP-4 (dipeptidyl peptidase-4) inhibitor that avoids repeated renal dose titration. Which agent is the best initial choice?
A) Linagliptin, because it is eliminated primarily by the biliary/fecal route as unchanged drug and requires no renal dose adjustment at any eGFR
B) Saxagliptin at the standard 5 mg dose, because it is unaffected by renal function
C) Sitagliptin at the standard 100 mg dose, because it needs no adjustment at this eGFR
D) Glipizide, because sulfonylureas are preferred in advanced CKD
E) Acarbose, because alpha-glucosidase inhibitors are first-line in stage 4 CKD
ANSWER: A
Rationale:
Linagliptin is eliminated primarily by biliary and fecal excretion of unchanged drug, so it requires no renal dose adjustment at any eGFR and avoids the titration the clinician wants to prevent, while as a DPP-4 (dipeptidyl peptidase-4) inhibitor it carries low hypoglycemia risk appropriate for an elderly faller.
Option B: Option B is incorrect because saxagliptin is renally excreted and requires dose reduction at low eGFR, so it is not unaffected by renal function.
Option C: Option C is incorrect because sitagliptin is renally excreted and requires reduction (for example, to 25 mg) at this eGFR, not the standard 100 mg.
Option D: Option D is incorrect because sulfonylureas raise hypoglycemia and fall risk and are not preferred in advanced CKD.
Option E: Option E is incorrect because acarbose is contraindicated in significant renal impairment due to metabolite accumulation.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. Suppose that instead of linagliptin she had been taking saxagliptin 5 mg daily, and she is now prescribed clarithromycin for pneumonia. What adjustment to the saxagliptin is appropriate?
A) No change, because saxagliptin is not metabolized by cytochrome P450 enzymes
B) Increase saxagliptin to 10 mg to overcome accelerated metabolism
C) Discontinue saxagliptin permanently, since it cannot be combined with any antibiotic
D) Replace saxagliptin with a high-dose sulfonylurea during antibiotic therapy
E) Reduce saxagliptin to 2.5 mg, because clarithromycin is a potent CYP3A4 inhibitor and saxagliptin is a CYP3A4 substrate
ANSWER: E
Rationale:
Saxagliptin is a CYP3A4 (cytochrome P450 3A4) substrate, and clarithromycin is a potent CYP3A4 inhibitor, so co-administration raises saxagliptin exposure; the appropriate adjustment is to reduce saxagliptin from 5 mg to 2.5 mg.
Option A: Option A is incorrect because saxagliptin is in fact a CYP3A4 substrate, so the interaction is real.
Option B: Option B is incorrect because clarithromycin inhibits rather than induces metabolism, so increasing the dose would worsen exposure.
Option C: Option C is incorrect because the interaction is managed by dose reduction, not permanent discontinuation, and does not apply to all antibiotics.
Option D: Option D is incorrect because substituting a high-dose sulfonylurea introduces unnecessary hypoglycemia risk and is not the indicated management.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. She is back on linagliptin, but remains above goal, so a sulfonylurea is added. Given her age and fall history, what should the clinician anticipate regarding hypoglycemia, and why?
A) Hypoglycemia risk is unchanged, because linagliptin neutralizes any sulfonylurea effect
B) Hypoglycemia risk falls, because two insulin-promoting agents trigger a protective glucagon surge
C) Hypoglycemia risk rises, because the sulfonylurea drives non-glucose-dependent insulin secretion that bypasses the glucose-dependent safety feature of the gliptin
D) Insulin secretion stops entirely, producing hyperglycemia rather than hypoglycemia
E) The sulfonylurea is inactivated by the gliptin, so no additional effect occurs
ANSWER: C
Rationale:
The low hypoglycemia risk of gliptin monotherapy reflects glucose-dependent insulin secretion that ceases as glucose normalizes; a sulfonylurea stimulates insulin secretion in a non-glucose-dependent manner, so adding it bypasses that safety feature and raises hypoglycemia risk, a particular concern in an elderly faller.
Option A: Option A is incorrect because linagliptin does not neutralize the sulfonylurea's independent secretagogue action.
Option B: Option B is incorrect because combining two insulin-promoting agents increases, not decreases, hypoglycemia risk and does not trigger a protective glucagon surge.
Option D: Option D is incorrect because insulin secretion is enhanced, not abolished, tending toward hypoglycemia rather than hyperglycemia.
Option E: Option E is incorrect because the gliptin does not inactivate the sulfonylurea; both contribute to glucose lowering.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. A review of old records reveals she has a documented history of heart failure. Considering this within the DPP-4 (dipeptidyl peptidase-4) inhibitor class, which statement is correct?
A) All gliptins increase heart failure hospitalization equally, so the class should be stopped
B) Continuing linagliptin is appropriate, because sitagliptin and linagliptin did not show an excess heart failure hospitalization signal, whereas saxagliptin and alogliptin did
C) She should be switched to saxagliptin, which has the most reassuring heart failure data
D) Alogliptin is the safest gliptin in heart failure and should be substituted
E) Heart failure status has no relationship to gliptin selection
ANSWER: B
Rationale:
The heart failure hospitalization signal among gliptins is agent-specific: saxagliptin increased heart failure hospitalization in its cardiovascular outcome trial and alogliptin showed a directionally similar signal, whereas sitagliptin and linagliptin did not; continuing linagliptin is therefore appropriate in a patient with heart failure.
Option A: Option A is incorrect because the risk is not a uniform class effect, so blanket discontinuation is unwarranted.
Option C: Option C is incorrect because saxagliptin carries the signal and is not the reassuring choice.
Option D: Option D is incorrect because alogliptin shows a directionally similar signal and is not the safest in heart failure.
Option E: Option E is incorrect because heart failure status directly informs gliptin selection within the class.
9. [CASE 3 — QUESTION 1]
A 61-year-old woman with type 2 diabetes has well-controlled fasting glucose but persistent postprandial spikes despite metformin. She is weight-conscious, wishes to avoid hypoglycemia, and is willing to manage gastrointestinal side effects. Her renal function is normal. Which add-on agent is the most mechanistically rational choice for her glycemic phenotype?
A) Glipizide, because secretagogues preferentially target postprandial glucose without hypoglycemia
B) Pioglitazone, because it rapidly lowers postprandial glucose within days
C) Saxagliptin, because it is the only agent that affects postprandial glucose
D) Acarbose, because alpha-glucosidase inhibition slows complex-carbohydrate digestion, blunting postprandial excursions without causing hypoglycemia or weight gain
E) A sulfonylurea plus insulin, because combination secretion is required for postprandial control
ANSWER: D
Rationale:
Acarbose competitively inhibits brush-border alpha-glucosidases, slowing complex-carbohydrate digestion and preferentially attenuating postprandial glucose excursions; it does not stimulate insulin secretion, so it neither causes hypoglycemia as monotherapy nor produces weight gain, aligning well with this weight-conscious patient's isolated postprandial phenotype.
Option A: Option A is incorrect because sulfonylureas act by non-glucose-dependent secretion and carry hypoglycemia risk, contrary to her goals.
Option B: Option B is incorrect because pioglitazone has a delayed onset of weeks and does not specifically target postprandial glucose.
Option C: Option C is incorrect because DPP-4 (dipeptidyl peptidase-4) inhibitors are not the only agents affecting postprandial glucose, and acarbose is the targeted postprandial agent here.
Option E: Option E is incorrect because adding a sulfonylurea plus insulin introduces substantial hypoglycemia and weight risk that conflict with her priorities.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. Acarbose is selected. To minimize the gastrointestinal adverse effects that commonly limit alpha-glucosidase inhibitor use, what is the most appropriate prescribing and counseling approach?
A) Start at a low dose (for example, 25 mg with the first bite of one meal daily) and titrate up gradually over weeks, because flatulence and bloating arise from colonic fermentation of undigested carbohydrate and improve with slow escalation
B) Start at the maximum dose immediately to achieve rapid glycemic control
C) Take the dose two hours after meals to avoid contact with food
D) Take the dose at bedtime, independent of meals, to reduce daytime symptoms
E) Add a high-fiber supplement at initiation to accelerate dose escalation
ANSWER: A
Rationale:
The gastrointestinal effects of acarbose arise from colonic bacterial fermentation of carbohydrate that escapes proximal digestion; starting low (for example, 25 mg with the first bite of one meal daily) and titrating gradually over weeks allows adaptation and minimizes flatulence, bloating, and diarrhea.
Option B: Option B is incorrect because starting at the maximum dose maximizes fermentation-related symptoms and intolerance.
Option C: Option C is incorrect because acarbose must be taken with the first bite of a meal to inhibit digestion as carbohydrate arrives, not two hours afterward.
Option D: Option D is incorrect because bedtime dosing independent of meals misaligns the drug with carbohydrate intake.
Option E: Option E is incorrect because adding fiber does not enable faster escalation and may worsen gas and bloating.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. Months later, a sulfonylurea is added for additional control. She subsequently experiences a hypoglycemic episode (capillary glucose 50 mg/dL) and eats several sucrose-containing candies, but her glucose and symptoms do not improve. What is the correct treatment?
A) Give a larger second serving of sucrose candy
B) Give a complex-starch snack such as bread
C) Reassure her that acarbose prevents true hypoglycemia, so no treatment is needed
D) Withhold the next sulfonylurea dose and wait for spontaneous recovery
E) Give oral glucose tablets or gel, because acarbose blocks sucrose hydrolysis and only glucose will be absorbed quickly enough
ANSWER: E
Rationale:
Acarbose competitively inhibits brush-border alpha-glucosidases, blocking hydrolysis of sucrose and starch into absorbable monosaccharides, so sucrose fails to correct hypoglycemia; with a sulfonylurea on board, genuine hypoglycemia can occur and must be treated with oral glucose (tablets or gel), which is absorbed directly.
Option A: Option A is incorrect because additional sucrose remains poorly absorbed and will not correct the episode.
Option B: Option B is incorrect because starch also requires alpha-glucosidase digestion that acarbose blocks.
Option C: Option C is incorrect because adding a sulfonylurea makes real hypoglycemia possible, so treatment is required.
Option D: Option D is incorrect because symptomatic hypoglycemia requires prompt glucose, not passive waiting.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Over the following year her renal function declines, and her serum creatinine is now 2.3 mg/dL (estimated glomerular filtration rate [eGFR] 27 mL/min/1.73m2). What is the most appropriate action regarding her acarbose, despite the parent drug being minimally absorbed?
A) Continue acarbose unchanged, since less than 2 percent of the parent drug is absorbed
B) Double the acarbose dose to maintain efficacy as renal function declines
C) Discontinue acarbose, because its renally excreted bacterial degradation products accumulate and it is contraindicated in significant renal impairment
D) Continue acarbose and add a potassium binder to manage accumulation
E) Continue acarbose, because renal function does not affect alpha-glucosidase inhibitor safety
ANSWER: C
Rationale:
Although acarbose has minimal parent-drug absorption, colonic bacterial degradation products are absorbed and renally excreted, so they accumulate as renal function declines; acarbose is contraindicated in significant renal impairment (for example, serum creatinine above 2.0 mg/dL or eGFR below 30 mL/min/1.73m2), so at a creatinine of 2.3 mg/dL it should be discontinued.
Option A: Option A is incorrect because minimal parent-drug absorption does not make it safe; the metabolites are the concern.
Option B: Option B is incorrect because increasing the dose would worsen metabolite accumulation.
Option D: Option D is incorrect because the accumulating species are degradation products, not potassium, so a binder does not address the contraindication.
Option E: Option E is incorrect because renal function is directly relevant given renal excretion of the metabolites.
13. [CASE 4 — QUESTION 1]
A 55-year-old insulin-resistant man with type 2 diabetes has biopsy-proven non-alcoholic steatohepatitis (NASH) with significant steatosis and lobular inflammation. He has no heart failure, normal bone density, and no bladder pathology. His clinician wants an oral antidiabetic that also addresses the liver disease. Which agent has the strongest evidence in this setting?
A) Acarbose, because alpha-glucosidase inhibition reverses hepatic steatosis
B) Pioglitazone, because it has randomized trial evidence of histological improvement in NASH
C) Sitagliptin, because DPP-4 inhibitors are first-line therapy for NASH
D) Glipizide, because secretagogues reduce hepatic fat
E) Rosiglitazone, because it carries the strongest NASH evidence among thiazolidinediones
ANSWER: B
Rationale:
Pioglitazone is the only oral antidiabetic with consistent randomized trial evidence of histological improvement in NASH, reducing steatosis, lobular inflammation, and hepatocyte ballooning; with no heart failure, normal bone density, and no bladder pathology, the major thiazolidinedione liabilities do not apply.
Option A: Option A is incorrect because acarbose acts in the gut lumen and lacks NASH histological evidence.
Option C: Option C is incorrect because DPP-4 (dipeptidyl peptidase-4) inhibitors are not first-line for NASH and lack histological efficacy data.
Option D: Option D is incorrect because sulfonylureas do not improve hepatic histology in NASH.
Option E: Option E is incorrect because pioglitazone, not rosiglitazone, carries the NASH evidence, and rosiglitazone is generally avoided.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. He asks how pioglitazone helps his liver disease. Which statement best describes the mechanistic basis of pioglitazone's benefit in NASH?
A) PPAR-gamma activation redistributes lipid away from ectopic depots and improves insulin sensitization, reducing the hepatic lipotoxicity that drives steatohepatitis
B) Pioglitazone directly inhibits hepatic collagen synthesis, dissolving established fibrosis within days
C) Pioglitazone blocks intestinal fat absorption, preventing fat delivery to the liver
D) Pioglitazone suppresses bile acid synthesis, which clears hepatic fat
E) Pioglitazone acts as an antioxidant identical to vitamin E with no receptor involvement
ANSWER: A
Rationale:
Pioglitazone's benefit in NASH derives from PPAR-gamma (peroxisome proliferator-activated receptor gamma) activation, which redistributes lipid from ectopic depots (including the liver) toward subcutaneous adipose tissue and improves systemic insulin sensitivity, thereby reducing the hepatic lipotoxicity that drives steatohepatitis.
Option B: Option B is incorrect because pioglitazone does not directly dissolve established fibrosis within days; histological improvement is gradual and mediated through metabolic mechanisms.
Option C: Option C is incorrect because pioglitazone does not block intestinal fat absorption.
Option D: Option D is incorrect because it does not act by suppressing bile acid synthesis.
Option E: Option E is incorrect because pioglitazone acts through PPAR-gamma, a nuclear receptor, not as a receptor-independent antioxidant.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. Before pioglitazone is started, he mentions several weeks of painless gross hematuria that has not been evaluated. What is the most appropriate action?
A) Start pioglitazone immediately, since hematuria is unrelated to thiazolidinedione therapy
B) Start pioglitazone but order only a urine culture, with no further workup
C) Start pioglitazone at a reduced dose, which removes any bladder cancer concern
D) Defer pioglitazone and pursue urologic evaluation of the hematuria, because pioglitazone should be avoided with uninvestigated hematuria given its bladder cancer caution
E) Substitute rosiglitazone, which carries no bladder cancer concern and needs no workup
ANSWER: D
Rationale:
Pioglitazone carries an agent-specific bladder cancer caution, and guidance is to avoid it in patients with active bladder cancer or uninvestigated hematuria; painless gross hematuria in a 55-year-old warrants urologic evaluation before pioglitazone exposure, so the drug should be deferred.
Option A: Option A is incorrect because uninvestigated hematuria is exactly the setting where pioglitazone should be withheld.
Option B: Option B is incorrect because a urine culture alone is inadequate evaluation for painless gross hematuria.
Option C: Option C is incorrect because dose reduction does not eliminate the bladder cancer concern with uninvestigated hematuria.
Option E: Option E is incorrect because rosiglitazone is not a preferred substitute and substituting it does not address the need to investigate the hematuria.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. His hematuria is fully evaluated and found to be due to a benign cause, and he is cleared. He also had a transient ischemic attack (TIA) two months ago and remains markedly insulin-resistant. How does this history affect the rationale for pioglitazone?
A) It contraindicates pioglitazone, because any cerebrovascular event prohibits thiazolidinedione use
B) It is irrelevant, because pioglitazone has no evidence beyond glycemic control
C) It favors a sulfonylurea instead, which has proven cerebrovascular benefit
D) It favors acarbose, which is the agent of choice after a TIA
E) It strengthens the rationale, because in insulin-resistant patients with a recent cerebrovascular event pioglitazone reduced the risk of subsequent stroke or myocardial infarction
ANSWER: E
Rationale:
In insulin-resistant patients with a recent transient ischemic attack or stroke, pioglitazone reduced the risk of the composite of subsequent stroke or myocardial infarction, giving it an evidence-based secondary-prevention role that strengthens the rationale here, especially now that the hematuria has been cleared and the major thiazolidinedione liabilities are absent.
Option A: Option A is incorrect because a recent cerebrovascular event in an insulin-resistant patient is a setting of demonstrated pioglitazone benefit, not a contraindication.
Option B: Option B is incorrect because pioglitazone has well-established non-glycemic benefits, including in NASH and secondary prevention.
Option C: Option C is incorrect because sulfonylureas lack proven cerebrovascular benefit.
Option D: Option D is incorrect because acarbose is not the agent of choice after a TIA and lacks this secondary-prevention evidence.
17. [CASE 5 — QUESTION 1]
A 68-year-old man with type 2 diabetes is started on sitagliptin. His clinician explains why this agent carries a low risk of hypoglycemia. Which statement best captures the underlying incretin physiology?
A) Sitagliptin directly binds beta-cell ATP-sensitive potassium channels to trigger insulin release regardless of glucose
B) Sitagliptin suppresses all insulin secretion, preventing any glucose drop
C) Sitagliptin enhances incretin-mediated insulin secretion that is glucose-dependent and ceases as blood glucose normalizes, limiting hypoglycemia
D) Sitagliptin acts only in the gut lumen and has no systemic effect on insulin secretion
E) Sitagliptin stimulates counter-regulatory glucagon that offsets any fall in glucose
ANSWER: C
Rationale:
DPP-4 (dipeptidyl peptidase-4) inhibitors enhance the action of endogenous incretins, whose potentiation of insulin secretion is glucose-dependent and is extinguished as blood glucose normalizes; this glucose-dependence is the mechanistic basis for the low monotherapy hypoglycemia risk.
Option A: Option A is incorrect because closing beta-cell ATP-sensitive potassium channels regardless of glucose describes sulfonylureas, not gliptins.
Option B: Option B is incorrect because gliptins enhance rather than suppress insulin secretion.
Option D: Option D is incorrect because gliptins act systemically to potentiate insulin secretion, not solely in the gut lumen.
Option E: Option E is incorrect because GLP-1 (glucagon-like peptide-1) suppresses glucagon in a glucose-dependent manner rather than stimulating counter-regulatory glucagon.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. Over time his estimated glomerular filtration rate (eGFR) falls to 25 mL/min/1.73m2. Considering renal handling across the DPP-4 (dipeptidyl peptidase-4) inhibitor class, which statement is correct?
A) No gliptin requires any dose change with declining renal function
B) Sitagliptin requires an increased dose as eGFR falls to maintain efficacy
C) Linagliptin must be dose-reduced more aggressively than any other gliptin in CKD
D) All gliptins are contraindicated once eGFR falls below 30 mL/min/1.73m2
E) Sitagliptin should be dose-reduced (for example, to 25 mg) at this eGFR, whereas linagliptin requires no renal dose adjustment
ANSWER: E
Rationale:
Sitagliptin is primarily renally excreted and requires dose reduction (for example, to 25 mg once daily) at low eGFR, whereas linagliptin is eliminated by the biliary/fecal route and requires no renal dose adjustment at any eGFR.
Option A: Option A is incorrect because most gliptins do require dose adjustment as renal function declines.
Option B: Option B is incorrect because sitagliptin requires a reduced, not increased, dose at low eGFR.
Option C: Option C is incorrect because linagliptin needs no renal adjustment, so it is not the most aggressively reduced agent.
Option D: Option D is incorrect because the gliptins are not uniformly contraindicated below an eGFR of 30; they are dose-adjusted (or, for linagliptin, unchanged).
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. A colleague asks why saxagliptin, unlike sitagliptin, was associated with increased heart failure hospitalization, and whether a mechanism is established. Which statement is most accurate?
A) Saxagliptin directly blocks myocardial beta-adrenergic receptors, reducing contractility
B) DPP-4 also cleaves substrates such as SDF-1 and BNP, so enzyme inhibition may alter natriuretic-peptide and cardiac-remodeling biology; this is a proposed but not definitively established explanation for the saxagliptin heart failure signal
C) Saxagliptin causes the same ENaC-mediated sodium retention as the thiazolidinediones, which fully explains the signal
D) The signal is entirely explained by a cardiotoxic CYP3A4 metabolite unique to saxagliptin
DPP-4 (dipeptidyl peptidase-4) cleaves substrates beyond the incretins, including stromal cell-derived factor-1 (SDF-1) and BNP (B-type natriuretic peptide), so inhibiting the enzyme may alter natriuretic-peptide handling and cardiac-remodeling pathways; this is the leading proposed but not definitively established explanation for the saxagliptin heart failure signal.
Option A: Option A is incorrect because saxagliptin is not a beta-adrenergic receptor blocker.
Option C: Option C is incorrect because ENaC (epithelial sodium channel)-mediated sodium retention is the thiazolidinedione mechanism, not the gliptin mechanism, and does not fully explain the signal.
Option D: Option D is incorrect because the signal is not established as a CYP3A4 (cytochrome P450 3A4)-generated cardiotoxic metabolite.
Option E: Option E is incorrect because myocardial calcium chelation is not a recognized saxagliptin mechanism, and the substrate-biology hypothesis remains unproven rather than definitive.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. He read online that DPP-4 (dipeptidyl peptidase-4) inhibitors cause pancreatitis and is worried. Which statement most accurately reflects the current evidence?
A) Pooled cardiovascular outcome trial data across more than 45,000 patients did not confirm a statistically significant increase in confirmed acute pancreatitis, so it remains a listed precaution rather than a proven class hazard
B) Pancreatitis is a confirmed, statistically significant class-level hazard mandating avoidance of all incretin therapies
C) Pancreatitis risk has been definitively disproven and removed from all labeling
D) Pancreatitis risk applies only to patients without diabetes
E) The pancreatitis question was never studied in trials larger than 1,000 patients
ANSWER: A
Rationale:
The large dedicated cardiovascular outcome trials, pooled across more than 45,000 patients, did not confirm a statistically significant increase in confirmed acute pancreatitis with DPP-4 (dipeptidyl peptidase-4) inhibitors or liraglutide versus placebo; regulators concluded it is not a proven class hazard, though it remains a listed precaution given mechanistic plausibility.
Option B: Option B is incorrect because the data did not confirm a significant class-level hazard mandating avoidance.
Option C: Option C is incorrect because the risk has not been formally disproven and the precaution remains.
Option D: Option D is incorrect because the concern was studied in patients with diabetes, not confined to those without it.
Option E: Option E is incorrect because the question was specifically examined in very large outcome trials.
21. [CASE 6 — QUESTION 1]
A 76-year-old man on metformin has type 2 diabetes, irregular meals, prior falls, and stage 3 chronic kidney disease (CKD), with no heart failure and no atherosclerotic cardiovascular disease. Applying a comorbidity-driven framework to the agents in this module, which add-on best addresses the dominant clinical concern?
A) A thiazolidinedione, because insulin sensitization outweighs all other considerations in CKD
B) A sulfonylurea, because non-glucose-dependent secretion is ideal with irregular meals
C) An alpha-glucosidase inhibitor, because GI tolerability is rarely a problem at this age
D) A DPP-4 inhibitor (renally appropriate, such as linagliptin), because hypoglycemia avoidance and weight neutrality are the dominant concerns in an elderly faller with irregular meals and CKD
E) Rosiglitazone, because its cardiovascular profile is ideal for elderly patients
ANSWER: D
Rationale:
In an elderly faller with irregular meals and CKD but no heart failure or atherosclerotic disease, hypoglycemia avoidance and weight neutrality dominate; a DPP-4 (dipeptidyl peptidase-4) inhibitor fits this niche, and a renally appropriate agent such as linagliptin avoids titration.
Option A: Option A is incorrect because a thiazolidinedione adds fluid and fracture risk poorly suited to an elderly faller.
Option B: Option B is incorrect because a sulfonylurea's non-glucose-dependent secretion raises hypoglycemia risk, exactly what should be avoided here.
Option C: Option C is incorrect because alpha-glucosidase inhibitor GI tolerability is often worse, not negligible, and does not address the dominant hypoglycemia concern.
Option E: Option E is incorrect because rosiglitazone has an unfavorable cardiovascular profile and shares thiazolidinedione liabilities.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. He recalls that an older diabetes drug "was taken off the market for liver damage" and asks whether his options are safe. Which explanation correctly distinguishes troglitazone from the currently available thiazolidinediones?
A) Troglitazone caused hepatotoxicity through PPAR-gamma agonism, a property the other thiazolidinediones lack
B) Troglitazone's tocopherol (vitamin E) moiety is oxidized to a reactive quinone that causes idiosyncratic, non-dose-related hepatotoxicity; pioglitazone and rosiglitazone lack this moiety and do not generate the toxic metabolite
C) All three thiazolidinediones generate the same toxic metabolite, and troglitazone was simply dosed higher
D) Troglitazone was withdrawn for renal, not hepatic, toxicity unrelated to its structure
E) Pioglitazone and rosiglitazone are not metabolized at all, which is why they avoid hepatotoxicity
ANSWER: B
Rationale:
Troglitazone uniquely contains a tocopherol (vitamin E, alpha-tocopherol) moiety that is oxidized to a reactive quinone capable of forming protein adducts and causing idiosyncratic hepatotoxicity that is not dose-related at therapeutic doses; pioglitazone and rosiglitazone lack this moiety and do not generate the toxic metabolite, so they remained available.
Option A: Option A is incorrect because PPAR-gamma (peroxisome proliferator-activated receptor gamma) agonism is shared by all three agents and is not the basis of the hepatotoxicity.
Option C: Option C is incorrect because the other agents do not generate the troglitazone quinone metabolite; the difference is structural, not merely dosing.
Option D: Option D is incorrect because troglitazone was withdrawn for hepatotoxicity tied to its structure.
Option E: Option E is incorrect because pioglitazone and rosiglitazone are hepatically metabolized; they simply do not form the troglitazone toxic metabolite.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. He read that injectable diabetes drugs "work much better and cause weight loss" and asks why his oral gliptin does not. Which explanation correctly accounts for the difference?
A) DPP-4 inhibitors and GLP-1 receptor agonists produce identical incretin elevations, so the difference is adherence
B) The gliptin produces the larger incretin elevation, so the difference is paradoxical
C) DPP-4 inhibitors raise endogenous incretin levels only about 2-fold, whereas GLP-1 receptor agonists achieve a 5- to 8-fold elevation, and this larger effect drives both greater HbA1c reduction and the gastric-slowing and appetite effects that produce weight loss
D) GLP-1 receptor agonists work through renal glucose excretion, unrelated to incretin magnitude
E) The weight loss with agonists comes from ENaC-mediated fluid loss rather than any incretin effect
ANSWER: C
Rationale:
DPP-4 (dipeptidyl peptidase-4) inhibitors raise endogenous incretin concentrations only modestly (about 2-fold), whereas injectable GLP-1 (glucagon-like peptide-1) receptor agonists achieve a 5- to 8-fold elevation; the larger pharmacological effect drives both the greater HbA1c reduction and the gastric-emptying slowing and appetite suppression that produce weight loss, which the gliptin does not.
Option A: Option A is incorrect because the incretin elevations are not identical; the magnitudes differ substantially.
Option B: Option B is incorrect because the agonist, not the gliptin, produces the larger elevation, so the difference is expected.
Option D: Option D is incorrect because GLP-1 receptor agonists act through the incretin axis, not renal glucose excretion.
Option E: Option E is incorrect because the weight loss arises from incretin-mediated appetite and gastric effects, not ENaC (epithelial sodium channel)-related fluid loss.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. Considering the overall framework that governs antidiabetic selection across this module, which principle best summarizes the rational sequencing of therapy?
A) Agents with proven cardiovascular or cardiorenal outcome benefit are prioritized in patients with the relevant comorbidities, while glycemic-efficacy and tolerability considerations guide selection among the remaining agents such as DPP-4 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors
B) Agents should be ranked strictly by HbA1c-lowering potency, regardless of comorbidity
C) Thiazolidinediones should always be first-line because they address insulin resistance
D) Alpha-glucosidase inhibitors should be used first in all patients because of their luminal safety
E) DPP-4 inhibitors should be avoided in everyone because of the heart failure signal seen with saxagliptin
ANSWER: A
Rationale:
The governing framework prioritizes agents with proven cardiovascular or cardiorenal outcome benefit in patients who have the relevant comorbidities, then uses glycemic efficacy and tolerability to choose among the remaining agents (DPP-4 [dipeptidyl peptidase-4] inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors), each of which has a defined secondary niche.
Option B: Option B is incorrect because selection is comorbidity-driven rather than ranked purely by glycemic potency.
Option C: Option C is incorrect because thiazolidinediones occupy a specific niche, not a universal first-line role.
Option D: Option D is incorrect because alpha-glucosidase inhibitors have a limited, postprandial-focused niche, not a first-line role for all patients.
Option E: Option E is incorrect because the heart failure signal is agent-specific (saxagliptin and alogliptin), and sitagliptin and linagliptin remain appropriate, so the whole class is not avoided.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.